Success Metrics

Clinical Success Rate
84.0%

Based on 21 completed trials

Completion Rate
84%(21/25)
Active Trials
1(3%)
Results Posted
43%(9 trials)
Terminated
4(14%)

Phase Distribution

Ph phase_2
9
31%
Ph phase_3
10
34%
Ph not_applicable
4
14%
Ph phase_4
3
10%
Ph phase_1
3
10%

Phase Distribution

3

Early Stage

9

Mid Stage

13

Late Stage

Phase Distribution29 total trials
Phase 1Safety & dosage
3(10.3%)
Phase 2Efficacy & side effects
9(31.0%)
Phase 3Large-scale testing
10(34.5%)
Phase 4Post-market surveillance
3(10.3%)
N/ANon-phased studies
4(13.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

80.8%

21 of 26 finished

Non-Completion Rate

19.2%

5 ended early

Currently Active

1

trials recruiting

Total Trials

29

all time

Status Distribution
Active(1)
Completed(21)
Terminated(5)
Other(2)

Detailed Status

Completed21
Terminated4
unknown2
Withdrawn1
Active, not recruiting1

Development Timeline

Analytics

Development Status

Total Trials
29
Active
1
Success Rate
84.0%
Most Advanced
Phase 4

Trials by Phase

Phase 13 (10.3%)
Phase 29 (31.0%)
Phase 310 (34.5%)
Phase 43 (10.3%)
N/A4 (13.8%)

Trials by Status

withdrawn13%
active_not_recruiting13%
terminated414%
completed2172%
unknown27%

Recent Activity

Clinical Trials (29)

Showing 20 of 29 trialsScroll for more
NCT06120140Phase 2

Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib

Active Not Recruiting
NCT05479123Phase 4

Assessing the Impact of Dosage Frequency of Propranolol on Sleep Patterns in Patients With Infantile Hemangiomas

Terminated
NCT02422017Phase 2

Topical Timolol Benefit in Venous Ulcers

Completed
NCT02390284Phase 3

Stop Retinal Ganglion Cell Dysfunction Study

Terminated
NCT03282981Phase 3

Beta Adrenergic Antagonist for the Healing of Chronic DFU

Completed
NCT00579969Phase 2

Comparison of Latanoprost Vs. Timolol

Terminated
NCT00572936Phase 2

Circadian Rhythms of Aqueous Humor Dynamics in Humans

Completed
NCT02774590Phase 1

Timolol for the Treatment of Acne and Rosacea

Completed
NCT04868175Not Applicable

Interval Intraocular Pressure in Intravitreal Injection Study

Completed
NCT00159653Phase 3

A 12-Week, Randomized, Double-Masked, Parallel Group Comparison Of Evening Dosing With Xalacom In Subjects With Glaucoma

Completed
NCT00277498Phase 3

A 12-week, Randomized, Double-masked, Parallel Group Comparison of Evening Dosing With Xalacom in Subjects With Glaucoma

Completed
NCT00716859Phase 3

A Phase 3 Prospective, Randomized, Double-Masked, 12-Week, Parallel Group Study In Pediatric Subjects With Glaucoma.

Completed
NCT00751049Phase 3

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within the United Kingdom

Completed
NCT00751062Phase 3

A Study of Open Angle Glaucoma or Ocular Hypertension in Patients Within Scandinavia

Completed
NCT03836664Phase 2

A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine

Completed
NCT01533376Phase 1

Treatment of Port-wine Mark in Sturge-Weber Syndrome Using Topical Timolol

Terminated
NCT02742649Phase 1

A Study to Evaluate Efficacy and Safety of a Fixed Combination Ocular Insert in Participants With Open-angle Glaucoma or Ocular Hypertension

Completed
NCT01749930Phase 3

Comparing the Safety and Efficacy of BOL-303259-X Ophthalmic Solution With Timolol Maleate Ophthalmic Solution in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed
NCT02731287Phase 2

Topical Timolol for Infantile Hemangioma in Early Proliferative Phase

Completed
NCT01749904Phase 3

Comparing Safety and Efficacy of BOL-303259-X With Timolol Maleate in Subjects With Open-Angle Glaucoma or Ocular Hypertension

Completed

Drug Details

Intervention Type
DRUG
Total Trials
29